sisomicin has been researched along with meropenem in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Culebras, E; García-Salguero, C; Picazo, JJ; Rodríguez-Avial, I | 1 |
| Culebras, E; Pena, I; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
| Amin, AN; Cerceo, E; Deitelzweig, SB; Sherman, BM | 1 |
| Bail, L; da Silva Nogueira, K; Dalmolin, TV; Ito, CAS; Martins, AF; Martins, AS; Rocha, JLL; Serio, AW; Tuon, FF | 1 |
| Alharbi, A; Alshehri, S; Eljaaly, K; Ortwine, JK; Pogue, JM | 1 |
| Cebrik, DS; Cloutier, DJ; Connolly, LE; Dwyer, JP; Friedland, I; Keepers, TR; Komirenko, AS; Krause, KM; Miller, LG; Wagenlehner, FME | 1 |
| Clabots, C; Johnson, JR; Johnston, BD; Porter, SB; Thuras, P | 1 |
| Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K | 1 |
| Pregnolato, M; Taccani, M; Terreni, M | 1 |
| Kasimati, A; Magkafouraki, E; Maraki, S; Mavromanolaki, VE; Moraitis, P; Scoulica, E; Stafylaki, D | 1 |
| Bakkaloglu, Z; Demirbas, Z; Dizbay, M; Ozger, HS; Suzuk-Yildiz, S | 1 |
4 review(s) available for sisomicin and meropenem
| Article | Year |
|---|---|
Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Boronic Acids; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae Infections; Escherichia coli; Heterocyclic Compounds, 1-Ring; Hospitals; Humans; Klebsiella pneumoniae; Meropenem; Pseudomonas aeruginosa; Sisomicin; Tetracyclines; Thienamycins | 2016 |
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials as Topic; Colistin; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Randomized Controlled Trials as Topic; Sisomicin; United States; United States Food and Drug Administration; Urinary Tract Infections | 2019 |
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines | 2021 |
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines | 2021 |
1 trial(s) available for sisomicin and meropenem
| Article | Year |
|---|---|
Once-Daily Plazomicin for Complicated Urinary Tract Infections.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Patient Acuity; Sisomicin; Urinary Tract Infections | 2019 |
10 other study(ies) available for sisomicin and meropenem
| Article | Year |
|---|---|
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Cross Infection; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sisomicin; Thienamycins | 2015 |
In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae Infections; Fosfomycin; Humans; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Serratia marcescens; Sisomicin; Thienamycins; Tigecycline | 2015 |
Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenem-Resistant Enterobacteriaceae; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Sisomicin; Thienamycins | 2018 |
Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Genotype; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Phylogeny; Sisomicin; Young Adult | 2021 |
Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Boronic Acids; Ceftazidime; Drug Combinations; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Sisomicin; Tetracyclines | 2022 |
In Vitro Activity of Plazomicin Against Carbapenem Resistant Klebsiella pneumoniae Strains.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Gentamicins; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Sisomicin; Tobramycin | 2022 |